Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01124747 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01124747 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 12 participants.
The verdict
NCT01124747, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The objective of this study is to assess the systemic disposition of ASP1585 after oral administration of 14C-labeled drug in healthy male subjects.
Interventions
- DRUG ASP1585
- DRUG 14C-Labeled ASP1585
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01124747
The ClinicalTrials.gov registry entry for NCT01124747 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ASP1585 is the first listed.
NCT01124747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01124747 about?
NCT01124747 is a clinical study titled "A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug". The objective of this study is to assess the systemic disposition of ASP1585 after oral administration of 14C-labeled drug in healthy male subjects.
What is the current status of trial NCT01124747?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-04. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01124747?
The interventions under investigation include: ASP1585 (DRUG), 14C-Labeled ASP1585 (DRUG).
Who is sponsoring clinical trial NCT01124747?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.